Showing 654 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

Editor's pick
Achillion press release
18 September 2015
New & experimental hepatitis C treatment

Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission

Editor's pick
Bristol-Myers Squibb press release
15 September 2015
New & experimental hepatitis C treatment

Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® + EXVIERA® in Genotype 1 Hepatitis C Patients

Editor's pick
AbbVie press release
14 September 2015
New & experimental hepatitis C treatment

Hepatitis C patients in England denied lifesaving liver drug

Editor's pick
The Observer
18 August 2015
Access to healthcare

Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

Editor's pick
Intellectual Property Watch
4 August 2015
New & experimental hepatitis C treatment

FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

Editor's pick
AIDSMeds
27 July 2015
New & experimental hepatitis C treatment

FDA approves Technivie for treatment of chronic hepatitis C genotype 4

Editor's pick
FDA
27 July 2015
Pharmaceutical industry

TAG Pipeline Report

Editor's pick
TAG
17 July 2015
New & experimental hepatitis C treatment

Gilead pills priced at $1,000 a day are found cost-effective

Editor's pick
Bloomberg
14 July 2015
New & experimental hepatitis C treatment

Leading Canadian researcher calls for inclusion of co-infected people in large HCV clinical trials

Editor's pick
CATIE
7 July 2015
Access to healthcare

The Medicines Patent Pool Releases Independent Feasibility Studies on Hepatitis C and Tuberculosis

Editor's pick
Medicines Patent Pool
7 July 2015
New & experimental hepatitis C treatment

People with HIV and HCV co-infection who have fibrosis stages F2 and above should be prioritised for new anti-HCV therapies

News
2 July 2015
New & experimental hepatitis C treatment

FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

Editor's pick
Wall Street Journal (blog)
29 June 2015
Hepatitis C treatment

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

Editor's pick
AbbVie press release
24 June 2015
New & experimental hepatitis C treatment

Sofosbuvir plus daclatasvir for 12 weeks cures HCV for most people with HIV/HCV co-infection

News
3 June 2015
New & experimental hepatitis C treatment

Achillion partners with J&J to develop hepatitis C drugs

Editor's pick
Reuters
20 May 2015
New & experimental hepatitis C treatment

Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough

News
15 May 2015
New & experimental hepatitis C treatment

Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients

News
15 May 2015
New & experimental hepatitis C treatment

Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis

News
11 May 2015
New & experimental hepatitis C treatment

Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough

News
7 May 2015
New & experimental hepatitis C treatment

ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

Editor's pick
Viiv Healthcare press release
6 May 2015
New & experimental hepatitis C treatment

When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

News
1 May 2015
Hepatitis C treatment

Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C

News
28 April 2015
New & experimental hepatitis C treatment

Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants

News
28 April 2015